The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day
treatment of adult patients with acute bacterial sinusitis and to measure the amount of time
it takes for symptom relief. Avelox is currently not approved for the 5 day treatment of
acute bacterial sinusitis, therefore in this study Avelox is considered an investigational
drug. In this study Avelox will be compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination